Cancer Research UK logo.
SearchDonate
  • Search

A trial of datopotamab deruxtecan for breast cancer (TROPION-Breast01)

Overview

Cancer types:

Breast cancer, Secondary cancers

Status:

Results

Phase:

Phase 3

Details

This trial compared datopotamab deruxtecan and standard chemotherapy for breast cancer.

It was for people with breast cancer that:

  • couldn’t be removed with surgery or had spread to another part of the body

  • had large amounts of hormone receptors (hormone receptor positive or HR positive cancer)

  • had a small number of receptors for the protein HER2 (HER2 negative cancer)

The trial was open for people to join between 2021 and 2022. The team published the results in 2024.

Recruitment start: 18 October 2021

Recruitment end: 26 December 2022

How to join

Please note: In order to you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Professor Peter Schmid

Supported by

AstraZeneca

Last reviewed: 10 Mar 2025

CRUK internal database number: 17902

Help and support